Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 6 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Increased sales of the overseas core AVF (needles for hemodialysis), closed systems for drug preparation and administration, and products related to feeding and swallowing, together with progress in passing on higher costs resulting from rising prices, contributed to improved profitability. The extraordinary loss recorded in connection with the production site in South Korea exceeded the initial estimate.
Business restructuring loss of ¥934 million resulting from impairment of manufacturing equipment and disposal of inventories at the production site in South Korea
| Item | Details |
|---|---|
| Net Sales | ¥65,000 million → ¥65,845 million（+1.3%） |
| Operating profit | ¥200 million → ¥381 million（+90.7%） |
| Ordinary income | ¥200 million → ¥356 million（+78.3%） |
| Profit attributable to owners of the parent | ¥-800 million → ¥-783 million |
| Net income per share | -¥32.63 → -¥31.97 |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 6 February 2026 |
| Previous-period results | Net sales ¥69,749 million, operating profit ¥872 million, ordinary profit ¥514 million, net income attributable to owners of the parent ¥89 million, and basic earnings per share ¥3.65 (fiscal year ended March 2025) |
| Reason for the revision | Increased sales of the overseas core AVF (needles for hemodialysis), closed systems for drug preparation and administration, and products related to feeding and swallowing, together with progress in passing on higher costs resulting from rising prices, contributed to improved profitability. The extraordinary loss recorded in connection with the production site in South Korea exceeded the initial estimate. |
| Details and amount of extraordinary loss | Business restructuring loss of ¥934 million resulting from impairment of manufacturing equipment and disposal of inventories at the production site in South Korea |
| Dividend forecast revision | A year-end dividend of ¥8.50 per share is planned. Increase, decrease or no change: Not disclosed. |
| Consolidated / non-consolidated | Consolidated |
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In addition to increased sales of the overseas core AVF (needles for hemodialysis), domestic closed systems for drug preparation and administration, and products related to feeding and swallowing, the pass-through of higher costs resulting from rising prices contributed to improved profitability. Net income attributable to owners of the parent was broadly in line with the forecast because the extraordinary loss recorded in connection with the production site in South Korea exceeded the initial estimate.